SciClone Pharmaceuticals (SCLN +0.5%) updates its 2013 outlook, now expecting an initial EPS of...


SciClone Pharmaceuticals (SCLN +0.5%) updates its 2013 outlook, now expecting an initial EPS of $0.66 - $0.72 per share on revenues of between $150M - $155M. Analysts are looking for the company to earn $0.65 on revenue of around $152M.

Comments (1)
  • Remyngton
    , contributor
    Comments (343) | Send Message
     
    Talk about straddling the #'s
    7 Jan 2013, 03:52 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs